GlassScriptPhysician profile
Cesar H Trabanco
NPI 1104018654
$20,179.48
in general payments reported to CMS, 2019-2025
11 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,680 · 2021: $265 · 2022: $56.91 · 2023: $74.37 · 2024: $47.88 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.50 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,263.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $5,832.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $300.00 | 2019 | |
| Abbott Laboratories | $184.47 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Madrigal Pharmaceuticals | $148.27 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $127.93 | 2019 | |
| Corcept Therapeutics | $124.93 | 2021 | |
| Medtronic, INC. | $105.28 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Dexcom, INC. | $19.67 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Trabanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.